Read the latest news, insights, and expert advice from Stokes and our partners about veterinary medicine and animal care.
The following blog is written by Stokes Pharmacy’s Advisory Council member Jamie Rauscher, LVT. Jamie is the current president of the National Association of Veterinary Technicians in America, vice president of the Georgia Veterinary Technician & Assistant Association, and part owner and medical manager of the Animal Hospital of Towne
Compounded oral chemotherapy plays a vital role in veterinary oncology—particularly when commercial drugs aren’t available or when precise, individualized dosing is required. However, concerns persist about the accuracy and consistency of compounded formulations, which significantly impacts patient outcomes. Our recent study, published in Veterinary and Comparative Oncology (DOI: 10.1111/vco.13003
Stokes Pharmacy’s exclusive partnership with the Bova Group to bring safe, compounded treatment for feline infectious peritonitis (FIP) to the US brought a lot of excitement for veterinarians and pet owners looking to save cats with FIP. Not having access to treatment previously, Stokes’ release of Bova GS-441524 tablets was the first
Stokes Pharmacy and the Bova Group have almost parallel stories—pharmacies with retail roots that expanded into compounding to better serve a larger audience with the highest quality medications possible. Each organization has made a significant impact in the countries they serve—Stokes in the US and Bova in Australia and the
Stokes Pharmacy and Bova Partner Up to Treat FIP Stokes Pharmacy, a leading veterinary compounding pharmacy, announces an exclusive partnership with the Bova Group to offer a U.S.-made oral treatment for FIP, or Feline Infectious Peritonitis. Veterinarians will now be able to manage this once-fatal virus with Stokes Pharmacy’s compounded
Become a Stokes and Epicur insider to get our latest news and updates direct to your inbox.
